The US experience with cilostazol in treating intermittent claudication

Atherosclerosis Supplements

Volumn 6, Issue 4, 2005, Pages 21-31

  Hiatt, William R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antiplatelets; Cilostazol; Exercise therapy; Intermittent claudication; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MILRINONE; NIFEDIPINE; PENTOXIFYLLINE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROPIONYLCARNITINE; RAMIPRIL; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN;

ABNORMAL FECES; ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTERY DISEASE; ARTERY OCCLUSION; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CELLULITIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EXERCISE; FEMORAL ARTERY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PALPITATION; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; STROKE; SYNCOPE; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

EID: 32944464483     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2005.09.004     Document Type: Article

References (58)

1. H.G. Beebe, D.L. Dawson, and B.S. Cutler A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial Arch Intern Med 159 1999 2041 2050
2. D.L. Dawson, B.S. Cutler, and W.R. Hiatt A comparison of cilostazol and pentoxifylline for treating intermittent claudication Am J Med 109 2000 523 530
3. D.L. Dawson, B.S. Cutler, M.H. Meissner, and D.E. Strandness Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial Circulation 98 1998 678 686
4. M.B. Elam, J. Heckman, J.R. Crouse for the Cilostazol Lipid Investigators Study Group Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication Arterioscler Thromb Vasc Biol 18 1998 1942 1947
5. S.R. Money, J.A. Herd, and J.L. Isaacsohn Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease J Vasc Surg 27 1998 267 275
6. J.G. Regensteiner, J.E. Ware, and W.J. McCarthy Effect of cilostazol on treadmill walking, community-based walking ability, and health-related QOL in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials J Am Geriatr Soc 50 2002 1939 1946
7. D.E. Strandness, R. Dalman, and S. Panian Two doses of cilostazol versus placebo in the treatment of claudication: results of a randomized, multicenter trial Circulation 98 Suppl. 1 1998 12
8. E.R. Mohler Peripheral arterial disease: identification and implications Arch Intern Med 163 2003 2306 2314
9. M.H. Criqui, and J.O. Denenberg The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease Vasc Med 3 1998 241 245
10. J. Dormandy, L. Heeck, and S. Vig Lower-extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease Sem Vasc Surg 12 1999 118 122
11. J. Ness, and W.S. Aronow Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice J Am Geriatr Soc 47 1999 1255 1256
12. Z.-J. Zheng, A.R. Sharrett, and L.E. Chambless Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study Atherosclerosis 131 1997 115 125
13. W.S. Aronow, and C. Ahn Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women ≥62 years of age Am J Cardiol 74 1994 64 65
14. M.H. Criqui, R.D. Langer, and A. Fronek Mortality over a period of 10 years in patients with peripheral arterial disease N Engl J Med 326 1992 381 386
15. A.T. Hirsch, M.H. Criqui, and D. Treat-Jacobson Peripheral arterial disease detection, awareness, and treatment in primary care JAMA 286 2001 1317 1324
16. F.G.R. Fowkes, E. Housley, and E.H.H. Cawood Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population Int J Epidemiol 20 1991 384 392
17. W.T. Meijer, A.W. Hoes, and D. Rutgers Peripheral arterial disease in the elderly: the Rotterdam study Arterioscler Thromb Vasc Biol 18 1998 185 192
18. A.B. Newman, D.S. Siscovick, T.A. Manolio for the Cardiovascular Health Study Collaborative Research Group Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study Circulation 88 1993 837 845
19. A.B. Newman, K. Sutton-Tyrrell, G.H. Rutan, J. Locher, and L.H. Kuller Lower extremity arterial disease in elderly subjects with systolic hypertension J Clin Epidemiol 44 1991 15 20
20. M. Schroll, and O. Munck Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women J Chronic Dis 34 1981 261 269
21. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease Circulation 97 1998 425 428
22. E.K. Hoogeveen, P.J. Kostense, and P.J. Beks Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study Arterioscler Thromb Vasc Biol 18 1998 133 138
23. E.B. Jude, S.O. Oyibo, N. Chalmers, and A.J.M. Boulton Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome Diabetes Care 24 2001 1433 1437
24. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903.
25. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
26. S.A. Solomon, L.E. Ramsay, W.W. Yeo, L. Parnell, and W. Morris-Jones β blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination BMJ 303 1991 1100 1104
27. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
28. S.Z. Goldhaber, J.E. Manson, and M.J. Stampfer Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study Lancet 340 1992 143 145
29. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994;308:159-68.
30. G.P. Sachdev, K.D. Ohlrogge, and C.L. Johnson Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: outpatient management for adults Am J Health-Syst Pharm 56 1999 1505 1514
31. Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Fed Regist 1998;63:56802-17.
32. Current Controlled Trials. Randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis. Available at: http://www.controlled-trials.com/ isrctn/trial/%7C/0/66587262.html. Accessed February 25, 2005.
33. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
34. L.D. Fisher, M. Gent, and H.R. Buller Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo Am Heart J 141 2001 26 32
35. W.R. Hiatt Medical treatment of peripheral arterial disease and claudication N Engl J Med 344 2001 1608 1621
36. The Heart Outcomes Prevention Evaluations Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
37. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
38. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000;32(9 Suppl.):S498-S504.
39. W.R. Hiatt, E.E. Wolfel, J.G. Regensteiner, and E.P. Brass Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease J Appl Physiol 73 1992 346 353
40. W.R. Hiatt, D. Nawaz, and E.P. Brass Carnitine metabolism during exercise in patients with peripheral vascular disease J Appl Physiol 62 1987 2383 2387
41. A.W. Gardner, L.I. Kazel, J.D. Sorkin, and A.P. Goldberg Effects of long-term exercise rehabilitation on claudication distances in patients with peripheral arterial disease: a randomized controlled trial J Cardiopulm Rehabil 22 2002 192 198
42. A.W. Gardner, and E.T. Poehlman Exercise rehabiliation programs for the treatment of claudication pain: a meta-analysis JAMA 274 1995 975 980
43. B. Girolami, E. Bernardi, and M.H. Prins Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis Arch Intern Med 159 1999 337 345
44. G.C. Leng, B. Fowler, and E. Ernst Exercise for intermittent claudication (Cochrane Review) The Cochrane Library, Issue 3 2000 Update Software Oxford
45. K.J. Stewart, W.R. Hiatt, J.G. Regensteiner, and A.T. Hirsch Exercise training for claudication N Engl J Med 347 2002 1941 1951
46. TASC Working Group. Management of peripheral arterial disease (PAD): TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;1(Suppl):S1-S134.
47. F. Lindegärde, R. Jelnes, H. Björkman of the Scandinavian Study Group Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease Circulation 80 1989 1549 1556
48. C.M. Pratt Analysis of the cilostazol safety database Am J Cardiol 87 Suppl 2001 28D 33D
49. M. Packer, J.R. Carver, and R.J. Rodeheffer Effect of oral milrinone on mortality in severe chronic heart failure, The PROMISE Study Research Group N Engl J Med 325 1991 1468 1475
50. E.R. Mohler, W.R. Hiatt, M.A. Creager for the Study Investigators Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease Circulation 108 2003 1481
51. W.S. Aronow, D. Nayak, S. Woodsworth, and C. Ahn Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment Am J Cardiol 92 2003 711 712
52. S. Mondillo, P. Ballo, and R. Barbati Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease Am J Med 114 2003 359 364
53. R.J. Lederman, F.O. Mendelsohn, R.D. Anderson for the TRAFFIC Investigators Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial Lancet 359 2002 2053 2058
54. S. Rajagopalan, E.R. Mohler, and R.J. Lederman Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication Circulation 108 2003 1933 1938
55. G. Brevetti, S. Perna, C. Sabbá, V.D. Martone, and M. Condorelli Propionyl-l-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study J Am Coll Cardiol 26 1995 1411 1416
56. G. Brevetti, C. Diehm, D. Lambert for the Study Investigators European multicenter study on propionyl-l-carnitine in intermittent claudication J Am Coll Cardiol 34 1999 1618 1624
57. W.R. Hiatt, J.G. Regensteiner, and M.A. Creager Propionyl-l-carnitine improves exercise performance and functional status in patients with claudication Am J Med 110 2001 616 622
58. A.W. Bradbury The role of cilostazol (Pletal) in the management of intermittent claudication Int J Clin Pract 57 2003 405 409